Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Hemab Therapeutics Closes $157M Series C Led by Sofinnova Partners
Series CVenture Capital

Hemab Therapeutics Closes $157M Series C Led by Sofinnova Partners

•October 27, 2025
•Oct 27, 2025
0

Participants

Hemab

Hemab

company

Sofinnova Partners

Sofinnova Partners

investor

GQG

GQG

investor

Deal Summary

Hemab Therapeutics, a clinical-stage biotech focused on prophylactic treatments for bleeding and thrombotic disorders, raised $157M in a Series C financing. The round was led by Sofinnova Partners with participation from a large long-only global asset management company and additional new investors.

0

Comments

Want to join the conversation?

Loading comments...